

**Table 5** Selected Trials for Non-Small-Cell Lung Cancer (NSCLC)

Agent(s)	Patient Population	N	Overall ORR	Other ORR Data	Study [Reference]
Nivolumab	Chemonaive, first-line	20	30%	Nivolumab 3 mg/kg q2wk: 50% in PD-L1-positive 0% in PD-L1-negative	Gettinger et al[31]
Nivolumab	Heavily pretreated	129	17%	3% in 1 mg/kg q2wk 24.3% in 3 mg/kg q2wk 20.3% in 10 mg/kg q2wk 15% in PD-L1-positive 14% in PD-L1-negative	Brahmer et al[33]
Nivolumab + platinum-based doublet chemotherapy	Chemonaive, first-line	56	33% to 47% across four treatment arms	Gemcitabine/cisplatin + nivolumab 10 mg/kg q3wk: 33% Pemetrexed/cisplatin + nivolumab 10 mg/kg q3wk: 47% Paclitaxel/carboplatin + nivolumab 10 mg/kg q3wk: 47% Paclitaxel/carboplatin + nivolumab 5 mg/kg q3wk: 43%	Antonia et al[38]
Nivolumab + erlotinib	Chemonaive, EGFR-mutant	21	19%	1 patient with no prior EGFR tyrosine kinase inhibitor had near complete response	Rizvi et al[39]
Nivolumab + ipilimumab	Chemonaive, first-line	49	16%	Nivolumab 1 mg/kg + ipilimumab 3 mg/kg: 11% in squamous 13% in nonsquamous Nivolumab 3 mg/kg + ipilimumab 1 mg/kg: 33% in squamous 13% in nonsquamous	Antonia et al[37]
Pembrolizumab	Chemonaive, first-line, PD-L1-positive	45	26%	47% by irRC; durable	Rizvi et al[32]
Pembrolizumab	Previously treated NSCLC	194	20%	23% in PD-L1-positive 9% in PD-L1-negative	Garon et al[34]
MPDL3280A	Previously treated NSCLC	53	23%	83% (5/6) in IHC 3 PD-L1 ( 10% IC) 46% (6/13) in IHC 2/3 PD-L1 31% (8/26) in IHC 1-3 PD-L1 15% (4/27) in IHC 0 and unknown PD-L1 (negative)	Soria et al[35]
MEDI4736 at all doses	Previously treated NSCLC	155	16%	25% (5/20) in PD-L1-positive 3% (1/29) in PD-L1-negative	Brahmer et al[34]
MEDI4736 10 mg/kg q2w	Previously treated NSCLC	47	13%	39% (5/13) in PD-L1-positive 5% (1/19) in PD-L1-negative	Segal et al[19]

EGFR = epidermal growth factor receptor; IC = immune cells; IHC = immunohistochemistry; irRC = immune-related response criteria (investigator review); ORR = objective response rate; PD-L1 = programmed death ligand 1.